🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. BI 764198, Placebo to match BI 764198, BI 764198, BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 2 small molecule active

    1 trial

  2. BI 764524, Sham Injection Procedure

    Boehringer Ingelheim

    Diabetic retinopathy

    phase 2 small molecule active

    1 trial

  3. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim

    Solid tumours

    phase 2 small molecule active

    1 trial

  4. BI 907828, Ezabenlimab, BI 907828, BI 907828

    The George Institute

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  5. BI-754091 plus afatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule completed

    1 trial

  6. BLEOMYCIN, CISPLATIN

    Fondazione Telethon ETS

    patients with newly diagnosed or recurrent high-grade or initially invasive precancerous squamous lesions of the vulva and non-invasive vulvar Paget's disease

    phase 2 small molecule active

    1 trial

  7. BLEOPRIM 15 mg polvere per soluzione iniettabile, Carboplatino AHCL 10 mg/ml Concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    relapsing vulvar carcinoma already subjected to multiple treatments

    phase 2 small molecule active

    1 trial

  8. BNT111

    Regeneron UK Limited

    Melanoma Stage III

    phase 2 mab completed

    1 trial

  9. BNT111, LIBTAYO 350 mg concentrate for solution for infusion.

    BioNTech SE

    Melanoma (Stage III and IV)

    phase 2 small molecule active

    1 trial

  10. BNT116

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. BOOST cells

    The George Institute

    Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.

    phase 2 small molecule active

    1 trial

  12. BOTULINUM TOXIN , -

    The George Institute

    Myogenous temporomandibular disorders (TMDM)

    phase 2 small molecule active

    1 trial

  13. BPF-CCRT (run-in)

    Hospital Authority, Hong Kong

    Stage III Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. BPS804

    Mereo BioPharma Group plc

    Osteogenesis Imperfecta

    phase 2 small molecule terminated

    1 trial

  15. BPS804

    Ultragenyx UK Limited

    Osteogenesis Imperfecta

    phase 2 small molecule completed

    1 trial

  16. BPS804

    Mereo BioPharma Group plc

    Chronic-kidney Disease Stage 5D on Stable Hemodialysis

    phase 2 small molecule terminated

    1 trial

  17. BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets

    AXIM BIOTECHNOLOGIES, INC.

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

  18. BUL02, Placebo orodispersible tablets, BUL03

    Dr. Falk Pharma GmbH

    Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection

    phase 2 small molecule active

    1 trial

  19. Bacteriophage

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 small molecule terminated

    1 trial

  20. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Urinary Tract Infection Bacterial

    phase 2 mab terminated

    1 trial

  21. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Osteomyelitis

    phase 2 mab terminated

    1 trial

  22. Baritinib

    The First People's Hospital of Lianyungang

    Intracerebral Hemorrhage

    phase 2 small molecule completed

    1 trial

  23. Becotatug Vedotin

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  24. Belzutifan

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources